💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ticrynafen

CHEMBL267744 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
331.2 g/mol
LogP
4.1
Phase
4

Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

น้ำหนักโมเลกุล

331.2000 g/mol

LogP

4.10

TPSA

91.80 Ų

Lipinski RO5

ผ่าน

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)

                

                

                

                    
                    

                        
Molecular Formula

                        
C13H8Cl2O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
พันธะที่หมุนได้

                        
5

                    

                    
                    
                    

                        
อะตอมหนัก

                        
20

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Ticrynafen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL267744.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 38409.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.